Senior​/Principal Scientist, Radiochemistry

Job Title: Senior/Principal Scientist, Radiochemistry

Job Number: 37256

Location: New York, NY

You will join a fast-paced, science-driven biotech developing first-in-class targeted radio therapies with the potential to transform outcomes across solid tumors. The ideal candidate is an expert in radiochemistry, radiometal chelation, and radio conjugate design, with deep experience spanning both therapeutic and imaging radionuclides (e.g., Ac-225, Lu-177, Zr-89, In-111, Cu-64, Ga-68). A strong track record in PET/SPECT imaging agent development, chelator optimization, and structure-function evaluation is highly desirable.

• Provide scientific leadership across internal programs, defining innovation priorities for radiochemistry and radio conjugate development.
• Design, synthesize, and optimize chelators and bifunctional chelators for 225,177, and imaging isotopes; evaluate stability, radiolabeling kinetics, and in vivo performance.
• Lead conjugation, radiolabeling, and purification workflows (e.g., Ac-225, Lu-177, Zr-89, In-111; antibodies, minibodies, peptides, nanobodies) to support therapeutic and diagnostic programs.
• Develop PET and SPECT imaging agents to enable patient selection, target validation, PK/PD assessment, and dosimetry for targeted radiotherapy programs for Oncology.
• Drive experimental design and execution of radiochemistry studies, including analytical characterization (radio-HPLC, radio-TLC, gamma spectrometry, radioactivity measurement).
• Partner cross-functionally with In Vitro Biology, In Vivo Pharmacology, Translational Sciences, and CMC to advance programs through IND and early clinical development.
• Author nonclinical study reports, CMC sections, and radiochemistry content for regulatory filings (IND, IMPD, patent applications).
• Expand and IP including new linker design, new chelators, radioconjugation strategies, radiolabeling innovations, and structure-activity insights.
• Manage external collaborations and CRO relationships, including academic radiochemistry labs and imaging centers.

• Ph.D. in Radiochemistry, Organic Chemistry, Radiopharmaceutical Sciences, Nuclear Pharmacy, or related field.
• 8-10+ years of industry/academic experience developing targeted radio therapies and/or radiopharmaceutical imaging agents (PET/SPECT), from discovery through IND filings.
• Extensive hands‑on expertise with radiometal chelation, bifunctional chelator design (e.g., DOTA and emerging ligand systems), and bioconjugation chemistry.
• Demonstrated experience with therapeutic isotopes (Ac-225, Lu-177) and imaging isotopes (Zr89, Cu-64, In-111, Ga-68) including radiolabeling, purification, stability studies, and in vivo translation.
• Strong track record in developing PET/SPECT imaging agents, imaging‑guided dosimetry, and translational radionuclide imaging.
• Expertise with analytical and radio chemical instrumentation (size‑exclusion HPLC, radio‑HPLC, radio‑TLC, gamma spectrometry, LC‑MS a plus).
• Proven ability to lead programs through preclinical development into regulatory submission, with authorship of publications, patents, or regulatory documents.
• Strong critical thinking, creativity, and scientific curiosity, with an entrepreneurial mindset and ability to thrive in a fast‑growing biotech environment.
• Exceptional written and oral communication skills, with the ability to influence across functions and present to technical and non‑technical audiences.